Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Jun
15
Today In Oncology
Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy
HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Diagnostic Accuracy of Navigational Bronchoscopy vs Transthoracic Needle Biopsy in Lung Nodules
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo